Clinical Trials Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103855
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103855
Combining immune checkpoint inhibitors with standard treatment regimens in advanced human epidermal growth factor receptor-2 positive gastric cancer patients
Sheng-Hu Zhang, Wan Li, Xi-Yan Chen, Le-Le Nie
Sheng-Hu Zhang, Department of Oncology, Jingzhou Central Hospital, Jingzhou Hospital Affiliated to Yangtze university, Jingzhou 434020, Hubei Province, China
Wan Li, Department of Ultrasound Medicine, Jingzhou Central Hospital, Jingzhou Hospital Affiliated to Yangtze university, Jingzhou 434020, Hubei Province, China
Xi-Yan Chen, Department of Medicine Imaging, The First People’s Hospital of Fuzhou City, Fuzhou 344000, Jiangxi Province, China
Le-Le Nie, Department of General Surgery, The First People’s Hospital of Fuzhou City, Fuzhou 344000, Jiangxi Province, China
Co-first authors: Sheng-Hu Zhang and Wan Li.
Author contributions: Zhang SH designed the research study; Li W, Chen XY performed the research; Nie LL conducted experiments, analyzed the data; All authors contributed to editorial changes in the manuscript, read and approved the final manuscript.
Institutional review board statement: This study was approved by the ethics committee of the First People’s Hospital of Fuzhou City (No. FZ202103).
Clinical trial registration statement: This trial was not registered. The local IRB was aware of the trial and approved study.
Informed consent statement: Informed consent was obtained from all study participants.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Le-Le Nie, Chief Physician, Department of General Surgery, The First People’s Hospital of Fuzhou City, No. 1099 Yingbin Avenue, Fuzhou 344000, Jiangxi Province, China. nielele520@163.com
Received: December 20, 2024
Revised: January 12, 2025
Accepted: February 7, 2025
Published online: April 15, 2025
Processing time: 95 Days and 4.9 Hours
Core Tip

Core Tip: Immune checkpoint inhibitors combined with standard treatment regimens for patients with advanced human epidermal growth factor receptor 2-positive gastric cancer demonstrate favorable clinical efficacy, significantly prolonging progression-free survival with manageable safety. Eastern Cooperative Oncology Group performance status, peritoneal metastasis, positive programmed death-ligand 1 expression, and treatment regimen are independent factors influencing progression-free survival, warranting increased clinical attention to patients exhibiting these factors.